You are leaving the Canadian PNH Network site to go to an external site.

To C.A.T.C.H. PNH, know who’s at risk

Screen your patient. Early intervention is critical1

International Clinical Cytometry Society Guidelines recommend evaluation of the following higher-risk patient populations2,3

  • C

    Cytopenia, unexplained
  • A

    AA/RA-MDS
  • T

    Thrombosis, unexplained
  • C

    Coombs-negative
    hemolytic anemia
  • H

    Hemoglobinuria
Incidence of PNH clone4*
  • 5.7%
  • 26.3% /5.5%
  • 1.4%
  • 22.7%
  • 18.9%

*0.01% PNH cell threshold. Includes all MDS subtypes. AA=Aplastic anemia; RA-MDS=Refractory anemia myelodysplastic syndromes; PNH=Paroxysmal nocturnal hemoglobinuria
Study description: An analysis of the incidence of PNH clones in 6897 patients recommended for testing according to guidelines from the ICCS and the IPIG.

Rule PNH in or out using high-sensitivity flow cytometry and comprehensive clinical assessment

  • Identification of PNH cells has important prognostic and therapeutic implications5,6
  • ICCS guidelines and the International PNH Interest Group (IPIG) recommend continued monitoring of patients at higher risk for PNH2,5
  • The availability of an effective PNH treatment option warrants testing in higher risk patient populations7,8
References

Connect with your local PNH Expert to find a PNH testing centre near you

References

  1. Santarone S, Bacigalupo A, Risitano AM, et al. Hematopoietic stem cell transplantation for paroxysmal nocturnal hemoglobinuria: long-term results of a retrospective study on behalf of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Haematologica. 2010;95:983-988.
  2. Borowitz MJ, Craig FE, DiGiuseppe JA, et al. On behalf of the Clinical Cytometry Society. Guidelines for the diagnosis and monitoring of PNH and related disorders by flow cytometry. Cytometry Part B Clin Cytom. 2010;78B:211-230.
  3. Richards SJ, Barnett D. The role of flow cytometry in the diagnosis of PNH in the clinical laboratory. Clin Lab Med. 2007;27:577-590.
  4. Movalia M, Illingworth A, Weitz I, et al. Poster presented at the 53rd Annual Meeting of the American Society of Hematology; December 10-13, 2011; San Diego, CA. Abstract 1033.
  5. Parker C, Omine M, Richards S, et al. for the International PNH Interest Group. Blood. 2005;106:3699-3709.
  6. Dunn DE, Tanawattanacharoen P, Boccuni P, et al. Ann Intern Med. 1999;131:401-408.
  7. Borowitz MJ, Craig FE, DiGiuseppe JA, et al;for Clinical Cytometry Society. Cytometry Part B. 2010;78B:211-230.
  8. Hillmen P, Muus P, Röth A, et al. Br J Haematol. 2013;162:62-73.